Improving the topical delivery of zinc phthalocyanine using oleic acid as a penetration enhancer: In vitro permeation and retention

Drug Development and Industrial Pharmacy

Volumn 37, Issue 5, 2011, Pages 569-575

  Da Silva, Eduardo Rodrigues ^a   Faria De Freitas, Zaida Maria ^a   Brito Gitirana, Lycia De ^a   Ricci Júnior, Eduardo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

cutaneous delivery; photodynamic therapy; Photosensitizer; skin cancer

Indexed keywords

OLEIC ACID; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ZINC; PROPYLENE GLYCOL; TEMOPORFIN;

ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; EMISSION TOMOGRAPHY; IN VITRO STUDY; NONHUMAN; PHOTODYNAMIC THERAPY; SKIN; SKIN CANCER;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EAR, EXTERNAL; INDOLES; OLEIC ACID; ORGANOMETALLIC COMPOUNDS; PERMEABILITY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROPYLENE GLYCOL; SKIN; SKIN NEOPLASMS; SWINE;

EID: 79953771170     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.529144     Document Type: Article

References (47)

1. Bagnato VS, Kurachi C, Ferreira J, Marcassa LG, Sibata CH, Allison RR. (2005). PDT experience in Brazil: A regional profile. Photodiag Photodyn, 2:107-118. (Pubitemid 41160480)
2. Barry BW. (1987). Mode of action of penetration enhancers in human skin. J Control Resease, 6:85-97. (Pubitemid 18017724)
3. Barry BW. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci, 14:101-114. (Pubitemid 32737532)
4. Boiy A, Roelandts R, de Witte PA. (2007). Influence of application and formulation factors on the penetration of hypericin in normal mouse skin and UV induced skin tumors. J Photochem Photobiol B, Biol, 89:156-162. (Pubitemid 350154475)
5. Brown SB, Brown EA, Walker I. (2004). The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol, 5:497-508. (Pubitemid 39069400)
6. Castano AP, Demidova T, Hamblim MR. (2005). Mechanisms in photodynamic therapy: Party one photosensitizers, photochemistry and cellular localization. Photodiag Photodyn, 2:91-106.
7. Choi A, Gang H, Chun I, Gwak H. (2008). The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm, 357:126-131.
8. Dai T, Huang YY, Hamblin MR. (2009). Photodynamic therapy for localized infections-state of the art. Photodiagnosis Photodyn Ther, 6:170-188.
9. Davies MJ. (2003). Singlet oxygen-mediated damage to proteins and its consequences. Biochem Biophys Res Commun, 305:761-770. (Pubitemid 36579294)
10. De Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MV. (2000). A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release, 65:359-366. (Pubitemid 30122938)
11. De Rosa FS, Tedesco AC, Lopez RF, Pierre MB, Lange N, Marchetti JM et al. (2003). In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J Control Release, 89:261-269. (Pubitemid 36507020)
12. Duffy JF, Dijk DJ, Klerman EB, Czeisler CA. (1998). Later endogenous circadian temperature nadir relative to an earlier wake time in older people. Am J Physiol, 275:R1478-R1487.
13. Gwak HS, Chun IK. (2002). Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharm, 236:57-64. (Pubitemid 34219373)
14. Gwak HS, Oh IS, Chun IK. (2004). Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm, 30:187-194. (Pubitemid 38420263)
15. Hopper C. (2000). Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol, 1:212-219.
16. Hsu L-R, Huang Y-B, Wu P-C, Tsai Y-H. (1994). Percutaneous absorption of piroxicam from Fapg base through rat skin: effects of oleic acid and saturated fatty acid added to Fapg base. Drug Dev Ind Pharm, 20:1425-1437. (Pubitemid 24201247)
17. Ibbotson SH. (2006). How we treat a superficial basal cell carcinoma with topical photodynamic therapy in Dundee. Photodiag Photodyn, 3:128-131. (Pubitemid 44209003)
18. Ibbotson SH. (2010). An overview of topical photodynamic therapy in dermatology. Photodiagnosis Photodyn Ther, 7:16-23.
19. Jantharaprapap R, Stagni G. (2007). Effects of penetration enhancers on in vitro permeability of meloxicam gels. Int J Pharm, 343: 26-33. (Pubitemid 47321008)
20. Jung SY, Kang EY, Choi YJ, Chun IK, Lee BK, Gwak HS. (2009). Formulation and evaluation of ubidecarenone transdermal delivery systems. Drug Dev Ind Pharm, 35:1029-1034.
21. Kassab K, Fabris C, Defilippis MP, Dei D, Fantetti L, Roncucci G et al. (2000). Skin-photosensitizing properties of Zn(II)-2(3), 9(10), 16(17), 23(24)-tetrakis-(4-oxy-N-methylpiperidinyl) phthalocyanine topically administered to mice. J Photochem Photobiol B, Biol, 55:128-137. (Pubitemid 30440481)
22. Kiernan JA. (1990). Histological & Histochemical Methods: Theory and Practice, 2nd edn. Frankfurt, Germany: Pergamon Press.
23. Kim D-D, Chien YW. (1996). Comparison of skin permeation of dideoxynucleoside-type anti-HIV drugs: alone versus combination. Drug Dev Ind Pharm, 22:1047-1054. (Pubitemid 26389960)
24. Larrucea E, Arellano A, Santoyo S, Ygartua P. (2001). Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm, 52:113-119. (Pubitemid 32755888)
25. Lopez RF, Lange N, Guy R, Bentley MV. (2004). Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev, 56:77-94. (Pubitemid 38045425)
26. Lopes LB, Collett JH, Bentley MV. (2005). Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur J Pharm Biopharm, 60:25-30. (Pubitemid 40545857)
27. MacCormack MA. (2006). Photodynamic therapy. Adv Dermatol, 22:219-258. (Pubitemid 44960616)
28. Naik A, Pechtold LA, Potts RO, Guy RH. (1995). Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Release, 37:299-306. (Pubitemid 26007540)
29. Ogiso T, Iwaki M, Paku T. (1995). Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J Pharm Sci, 84:482-488.
30. Patel NA, Patel NJ, Patel RP. (2009). Design and evaluation of transdermal drug delivery system for curcumin as an antiinflammatory drug. Drug Dev Ind Pharm, 35:234-242.
31. Pierre MB, Ricci E Jr, Tedesco AC, Bentley MV. (2006). Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy. Pharm Res, 23:360-366. (Pubitemid 43237865)
32. Primo FJ, Michieleto L, Rodrigues MAM, Mararoff PP, Simioni AR, Morais PC, Bentley MVLB, Lacava ZGM, Tedesco AC. (2007). Magnetic nanoemulsions as drug delivery system for Foscan®: Skin permeation and retention in vitro assays for topical application in photodynamic therapy (PDT) of skin cancer. J Mag Mag Mater, 311:354-357. (Pubitemid 46401041)
33. Ren C, Fang L, Li T, Wang M, Zhao L, He Z. (2008). Effect of permeation enhancers and organic acids on the skin permeation of indapamide. Int J Pharm, 350:43-47.
34. Roberts DJ, Cairnduff F. (1995). Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg, 48:360-370.
35. Robertson CA, Evans DH, Abrahamse H. (2009). Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B, Biol, 96:1-8.
36. Santoyo S, Ygartua P. (2000). Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application. Eur J Pharm Biopharm, 50:245-250.
37. Schmidt-Erfurth U, Hasan T. (2000). Mechanisms of action of photodynamic therapy with verteporfin for the treatment of agerelated macular degeneration. Surv Ophthalmol, 45:195-214.
38. Sharman WM, van Lier JE, Allen CM. (2004). Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev, 56:53-76. (Pubitemid 38045424)
39. Singh SK, Roane DS, Reddy LK, Durrani MJ, Khan MA. (1996). Effect of additives on the diffusion of ketoprofen through human skin. Drug Dev Ind Pharm, 22:471-474. (Pubitemid 26170101)
40. Soni S, Jain SK, Jain NK. (1992). Effect of penetration enhancers on transdermal delivery of timolol maleate. Drug Dev Ind Pharm, 18: 1127-1135.
41. Squillante E, Maniar A, Needham T, Zia H. (1998). Optimization of in vitro nifedipine penetration enhancement through hairless mouse skin. Int J Pharm, 169:143-154. (Pubitemid 28345250)
42. Steluti R, De Rosa FS, Collett J, Tedesco AC, Bentley MV. (2005). Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin. Eur J Pharm Biopharm, 60:439-444. (Pubitemid 40922842)
43. Stief TW. (2003). The physiology and pharmacology of singlet oxygen. Med Hypotheses, 60:567-572. (Pubitemid 36315289)
44. Szeimies RM, Calzavara-Pinton P, Karrer S, Ortel B, Landthaler M. (1996). Topical photodynamic therapy in dermatology.
45. J Photochem Photobiol B, Biol, 36:213-219.
46. Thakur RA, Michniak BB, Meidan VM. (2007). Transdermal and buccal delivery of methylxanthines through human tissue in vitro. Drug Dev Ind Pharm, 33:513-521. (Pubitemid 46808772)
47. Yslas EI, Prucca C, Romanini S, Durantini EN, Bertuzzi M, Rivarola V. (2009). Biodistribution and phototherapeutic properties of Zinc (II) 2,9,16,23-tetrakis (methoxy) phthalocyanine in vivo. Photodiagnosis Photodyn Ther, 6:62-70.